Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED BALANCE SHEETS Statement [Table] Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] CURRENT ASSETS Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Other Assets, Current Other current assets Assets, Current TOTAL CURRENT ASSETS Assets TOTAL ASSETS Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity Liabilities, Current [Abstract] CURRENT LIABILITIES Accounts Payable, Current Accounts payable The amount of deferred fundraising receipts classified as current. Deferred Fundraising Receipts, Current Deferred fundraising receipts Accrued Liabilities, Current Accrued liabilities Employee-related Liabilities, Current Employee compensation and benefits Liabilities, Current TOTAL CURRENT LIABILITIES Liabilities TOTAL LIABILITIES Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES, see Note 3 Stockholders' Equity Attributable to Parent [Abstract] SHAREHOLDERS' EQUITY, see Note 4 Common Stock, Value, Issued Common Shares, $0.00001 par value - 60,000,000 shares authorized as of June 30, 2026, and December 31, 2025, 26,694,828, and 25,676,798 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the end Balance at the beginning TOTAL SHAREHOLDERS' EQUITY Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Common Stock, Par or Stated Value Per Share Common shares, par value (per share) Common Stock, Shares Authorized Common shares, shares authorized Common Stock, Shares, Issued Balance at the end (in shares) Balance at the beginning (in shares) Common shares, shares issued Common Stock, Shares, Outstanding Common shares, shares outstanding CONDENSED STATEMENTS OF OPERATIONS Operating Expenses [Abstract] OPERATING EXPENSES Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Income (Loss) OPERATING LOSS Amount of finance income. Finance Income Finance income Segment Loss NET LOSS Net loss Net Income (Loss) Available to Common Stockholders, Basic TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS Total net loss attributable to common shareholders Earnings Per Share, Basic BASIC NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 (in dollars per share) Basic net loss per common share Earnings Per Share, Diluted DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 (in dollars per share) Diluted net loss per common share Basic weighted average number of shares outstanding Basic weighted average number of common shares outstanding (in shares) Basic Weighted average of common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted weighted average number of common shares outstanding (in shares) Diluted Weighted average of common shares outstanding CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Represents information pertaining to public offering. Public Offering [Member] Public offering Represents the information pertaining at the market offering. At-the-Market At-the-Market At-the-market offering Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common shares Additional Paid-In Capital Additional Paid-In Capital Accumulated Deficit Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Share-based payments Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of restricted share awards (in shares) Stock Issued During Period, Value, New Issues Issuance of common shares, net of offering costs Stock Issued During Period, Shares, New Issues Issuance of common shares, net of offering costs (in shares) Number of shares issued Amount of cost incurred directly with the issuance of an equity security. Offering Costs Offering costs CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile loss to net cash used in operating activities: Share-based Payment Arrangement, Noncash Expense Cost of share-based payments Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Current Assets Increase in other current assets Increase (Decrease) in Accounts Payable (Decrease)/increase in accounts payable Increase (Decrease) in Accrued Liabilities Decrease in accrued liabilities The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Increase (Decrease) in Accrued Compensation and Benefits Decrease in employee compensation and benefits Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from Issuance of Common Stock Proceeds from issuance of common shares Payments of Stock Issuance Costs Issuance costs Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH AND CASH EQUIVALENTS AT END OF PERIOD CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD Noncash Investing and Financing Items [Abstract] Supplemental noncash disclosure of investing and financing activities: The amount of unpaid offering costs related to offering. Unpaid Issuance Costs Related to Offering Unpaid issuance costs related to public offering GENERAL Nature of Operations [Text Block] GENERAL SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] SIGNIFICANT ACCOUNTING POLICIES COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SHAREHOLDERS' EQUITY SHARE-BASED PAYMENTS Share-based Payment Arrangement [Text Block] SHARE-BASED PAYMENTS NET LOSS PER SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE SEGMENT REPORTING Segment Reporting Disclosure [Text Block] SEGMENT REPORTING SUBSEQUENT EVENTS. Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates in the Preparation of Financial Statements Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurement New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] SHARE-BASED PAYMENTS Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of restricted stock awards Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic net loss per share Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of weighted average of common shares outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities were excluded from the calculation of diluted net loss per common stock because their effect would have been anti-dilutive Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Schedule of Additional disaggregated significant segment expenses Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Represents the member information pertaining to public offering and overallotment option. Public Offering and Overallotment Option [Member] Public Offering and Overallotment Option Over-Allotment Option [Member] Underwriters option Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent events Subsequent events Subsidiary, Sale of Stock [Line Items] SHAREHOLDERS' EQUITY GENERAL Per share amount of equity securities sold during the period. Share Issued, Sale Price Per Share Average selling price per share Shares Issued, Price Per Share Sales price per share Sale of Stock, Consideration Received on Transaction Net proceeds Number of shares available under over allotment option. Shares Available For Issuance Under Over Allotment Option Shares available for underwriters option Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount1 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount1 Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. Fair Value, Assets, Level 2 to Level 1 Transfers, Amount1 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount1 Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount1 Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount1 Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount 1 Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount 1 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Amount of transfers into or out of Level 3 of the fair value, assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Amount of transfers into or out of Level 3 of the fair value, liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information pertaining to exclusive license agreement with Haisco Pharmaceutical Group Co., Ltd. Haisco License Agreement [Member] Haisco Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] COMMITMENTS AND CONTINGENCIES The amount of upfront payments under collaboration arrangement. Collaborative Arrangement, Upfront Payments Non refundable payment Represents the information pertaining to exclusive license agreement with the University Court of the University of Edinburgh ("UoE" or the "Parties") for the second drug candidate referred to as NXP900. University of Edinburgh License Agreement University of Edinburgh License Agreement Location, Statement of Income, Balance [Axis] Amount utilized from fund raising commitment under collaborative arrangement. Collaborative Agreement, Amount Utilized from Fund Raising Commitment Collaborative agreement, amount utilized from fund raising commitment The threshold payments associated with future find raising, under collaboration agreement. Collaborative Arrangement, Threshold Payments Related to Future Fund Raising Fund raised Loss Contingency, Estimate of Possible Loss Contingent liabilities Loss Contingency Accrual Provision made The information pertaining to At The Market Program. At The Market Program [Member] ATM Program The cash inflow from the additional capital contribution to the entity from gross amount. Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock Aggregate amount of common shares remaining available for future issuance. Common Stock, Securities Remaining Available For Future Issuance, Amount Common shares remaining available for future issuance Share Price Share price The amount of cash outflow associated with the payment of underwriting discounts and commissions. Payments of Underwriting Discounts and Commissions Underwriting discounts and commissions The amount of cash outflow associated with the payment of other offering expenses. Payments of Other Offering Expenses Other offering expenses Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Award Type [Domain] Represents the information pertaining to 2021 Global Equity Incentive Plan. Global Equity Incentive Plan 2021 [Member] 2021 Global Equity Incentive Plan Restricted Stock Restricted Stock Awards Unvested RSAs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding - June 30, 2026 (in shares) Balance, December 31, 2025 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that are expected to vest as of the balance sheet date. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Expected to vest - June 30, 2026 (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Outstanding - June 30, 2026 (in dollars per share) Balance, December 31, 2025 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) The weighted average fair value at grant date for nonvested equity-based awards expected to vest during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to vest, Weighted Average Grant Date Fair Value Expected to vest - June 30, 2026 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Weighted average contractual term and Aggregated intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Weighted average contractual term, outstanding (in years) Weighted average remaining contractual term for expected to vest equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Terms Weighted average contractual term, expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Aggregated Intrinsic value, outstanding Intrinsic value of expected to vest award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest Aggregated Intrinsic value, expected to vest Related Party [Axis] Related Party [Domain] Represents the information pertaining to Mr.Ron Bentsur. Mr.Ron Bentsur Mr.Ron Bentsur Represents the information pertaining to Dr.Enrique Poradosu. Dr.Enrique Poradosu Dr.Enrique Poradosu Represents the information pertaining to Mr.Shay Shemesh. Mr.Shay Shemesh Mr.Shay Shemesh Vesting [Axis] Vesting [Domain] First anniversary from the date of grant